MedAlliance

MedAlliance is a privately owned company dedicated to developing ground-breaking technology for the treatment of coronary and peripheral arterial disease.
Using breakthrough proprietary technology that combines the proven safety and efficacy of sirolimus with advanced MicroReservoir and Cell Adherent Technology (CAT™).
MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with their SELUTION SLR™ Technology.

www.medalliance.com

Highlighted Video

The Importance of No Slow Flow Phenomena

Watch Now Watch Now

Why sustained release matters?

Watch Now Watch Now

CAT™ balloon coating technology – 3 step mechanism of action

Watch Now Watch Now

PRESTIGE Study - 12 month results with the SELUTION Sirolimus Coated Balloon in TASC C and D tibial occlusive disease.

Watch Now Watch Now

An Italian Perspective on latest generation sirolimus DEBs + Clinical Case

Watch Now Watch Now

SELUTION SLR – Addressing unmet clinical needs

Watch Now Watch Now

SELUTION SLR – Cell Adherent Technology (CAT™)

Watch Now Watch Now

SELUTION SLR – Why sirolimus could offer clinical benefits over paclitaxel?

Watch Now Watch Now

SELUTION SLR – MicroReservoir Technology

Watch Now Watch Now

SELUTION SLR - Breakthrough Technology

Watch Now Watch Now

SELUTION SLR – Sustained Limus Release

Watch Now Watch Now

SELUTION SLR – First-in Human Clinical Data and Clinical Experience

Watch Now Watch Now